MORRISTOWN, N.J. — Alvogen Pharma US, Inc. has entered into a definitive agreement for its shareholders to sell the company to Lotus Pharmaceutical Co., Ltd. Once complete, the transaction will make Alvogen a controlled subsidiary of Lotus, expanding the Taiwanese company’s global reach and U.S. presence.
The deal deepens an existing collaboration between the two firms that has produced several successful co-developed launches. For Lotus, the acquisition provides access to Alvogen’s U.S. platform, including a dedicated sales force, in-house manufacturing at the Norwich, N.Y. facility, and a complementary R&D pipeline.
“This acquisition represents a culmination of Alvogen's operational excellence and targeted portfolio aimed at sustainable growth. Joining Lotus positions Alvogen for its next stage of expansion into multiple segments. With Lotus' global partnerships and APAC distribution, we expect to extend the reach of our specialized generics and brands while maintaining our commitment to quality and reliable supply from our Norwich facility,” said Lisa Graver, Chief Executive Officer, Alvogen.
Robert Wessman, Chairman of both Alvogen and Lotus, described the move as the natural next step in the companies’ partnership.
“We are excited to combine Alvogen with Lotus Pharmaceutical. This acquisition represents a natural evolution of our long-standing partnership and provides our specialty portfolio and dedicated team with a broader platform for growth and impact. Importantly, this deal is also a testament to Lotus' proven strategy — growing our presence in core areas in APAC and US, developing new opportunities through B2B and M&A, and bolstering our specialty pipeline. With this consistent vision, we will continue building a sustainable growth path and delivering value for patients and stakeholders globally.”
Jefferies LLC and Rothschild & Co served as joint financial advisors to Alvogen, with White & Case LLP providing legal counsel. Terms of the deal were not disclosed, and the agreement remains subject to customary closing conditions.
About Alvogen
Alvogen is a privately held U.S.-based pharmaceutical company focused on complex, high-value products such as inhalation therapies, long-acting injectables, peptides and 505(b)(2) brand products. The company operates a dedicated U.S. manufacturing facility and markets over 30 products, supported by a robust product pipeline.
About Lotus
Founded in 1966, Lotus is a global pharmaceutical company specializing in novel and generic medicines, with a best-in-class R&D and manufacturing base in Asia. Certified by regulatory agencies worldwide, Lotus has partnerships across the U.S., Europe, Japan, China and Brazil, with more than 250 commercialized products and a development pipeline exceeding 100 projects.
